ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


For a second year, ImCheck has been selected by the French Tech as one of the top 120 French startups and of the 9 biotech companies developing innovative therapies
Leadership & Corporate 
Read more
ImCheck Presents at SITC First Clinical Demonstration of Gamma Delta T Cell Activation and Tumor Infiltration with Positive Safety for ICT01
Science & Medicine 
Read more
ImCheck Announces Four ICT01 Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting
Science & Medicine 
Read more

BioCapital Europe

On  Mar 11, 2021 

Read more

Tumor Myeloid Microenvirenment Directed Therapeutics

From  Mar 16, 2021  to  Mar 18, 2021 

Read more

AACR Annual Meeting 2021, Week 1

From  Apr 10, 2021  to  Apr 15, 2021 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news